These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 24782291)
41. Pioglitazone improves insulin resistance and decreases blood pressure in adult patients with congenital adrenal hyperplasia. Kroese JM; Mooij CF; van der Graaf M; Hermus AR; Tack CJ Eur J Endocrinol; 2009 Dec; 161(6):887-94. PubMed ID: 19755409 [TBL] [Abstract][Full Text] [Related]
42. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study. Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631 [TBL] [Abstract][Full Text] [Related]
43. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts. Rasouli N; Kern PA; Elbein SC; Sharma NK; Das SK Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669 [TBL] [Abstract][Full Text] [Related]
44. Twelve weeks of pioglitazone therapy significantly attenuates dysmetabolism and reduces inflammation in continuous ambulatory peritoneal dialysis patients--a randomized crossover trial. Li Y; Xie QH; You HZ; Tian J; Hao CM; Lin SY; Zhu TY Perit Dial Int; 2012; 32(5):507-15. PubMed ID: 22383630 [TBL] [Abstract][Full Text] [Related]
45. Low dose prednisolone and insulin sensitivity differentially affect arterial stiffness and endothelial function: An open interventional and cross-sectional study. Petersons CJ; Mangelsdorf BL; Poljak A; Smith MD; Greenfield JR; Thompson CH; Burt MG Atherosclerosis; 2017 Mar; 258():34-39. PubMed ID: 28189039 [TBL] [Abstract][Full Text] [Related]
46. Peroxisome proliferator-activated receptor-gamma agonists in atherosclerosis: current evidence and future directions. Roberts AW; Thomas A; Rees A; Evans M Curr Opin Lipidol; 2003 Dec; 14(6):567-73. PubMed ID: 14624133 [TBL] [Abstract][Full Text] [Related]
47. Insulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patients. Esterson YB; Zhang K; Koppaka S; Kehlenbrink S; Kishore P; Raghavan P; Maginley SR; Carey M; Hawkins M J Investig Med; 2013 Dec; 61(8):1152-60. PubMed ID: 24141239 [TBL] [Abstract][Full Text] [Related]
48. Pioglitazone improves endothelial function in non-diabetic patients with coronary artery disease. Staniloae C; Mandadi V; Kurian D; Coppola J; Bernaski E; El-Khally Z; Morlote M; Pinassi E; Ambrose J Cardiology; 2007; 108(3):164-9. PubMed ID: 17077630 [TBL] [Abstract][Full Text] [Related]
49. Effects of pioglitazone in familial combined hyperlipidaemia. Abbink EJ; De Graaf J; De Haan JH; Heerschap A; Stalenhoef AF; Tack CJ J Intern Med; 2006 Jan; 259(1):107-16. PubMed ID: 16336518 [TBL] [Abstract][Full Text] [Related]
50. Association between insulin resistance and endothelial dysfunction in type 2 diabetes and the effects of pioglitazone. Suzuki M; Takamisawa I; Yoshimasa Y; Harano Y Diabetes Res Clin Pract; 2007 Apr; 76(1):12-7. PubMed ID: 17007957 [TBL] [Abstract][Full Text] [Related]
51. Effects of the peroxisome proliferator-activated receptor (PPAR)-gamma agonist pioglitazone on renal and hormonal responses to salt in diabetic and hypertensive individuals. Zanchi A; Maillard M; Jornayvaz FR; Vinciguerra M; Deleaval P; Nussberger J; Burnier M; Pechere-Bertschi A Diabetologia; 2010 Aug; 53(8):1568-75. PubMed ID: 20414637 [TBL] [Abstract][Full Text] [Related]
52. Pilot study of pioglitazone and exercise training effects on basal myocardial substrate metabolism and left ventricular function in HIV-positive individuals with metabolic complications. Cade WT; Reeds DN; Overton ET; Herrero P; Waggoner AD; Laciny E; Bopp C; Lassa-Claxton S; Gropler RJ; Peterson LR; Yarasheski KE HIV Clin Trials; 2013; 14(6):303-12. PubMed ID: 24334183 [TBL] [Abstract][Full Text] [Related]
54. PPAR gamma agonists partially restores hyperglycemia induced aggravation of vascular dysfunction to angiotensin II in thoracic aorta isolated from rats with insulin resistance. Gaikwad AB; Viswanad B; Ramarao P Pharmacol Res; 2007 May; 55(5):400-7. PubMed ID: 17369046 [TBL] [Abstract][Full Text] [Related]
55. Effect of pioglitazone on insulin sensitivity, vascular function and cardiovascular inflammatory markers in insulin-resistant non-diabetic Asian Indians. Raji A; Gerhard-Herman MD; Williams JS; O'connor ME; Simonson DC Diabet Med; 2006 May; 23(5):537-43. PubMed ID: 16681563 [TBL] [Abstract][Full Text] [Related]
57. Long-term effects of a PPAR-gamma agonist, pioglitazone, on neointimal hyperplasia and endothelial regrowth in insulin resistant rats. Desouza CV; Gerety M; Hamel FG Vascul Pharmacol; 2007 Mar; 46(3):188-94. PubMed ID: 17141574 [TBL] [Abstract][Full Text] [Related]
58. Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus. Bajaj M; Suraamornkul S; Hardies LJ; Glass L; Musi N; DeFronzo RA Diabetologia; 2007 Aug; 50(8):1723-31. PubMed ID: 17520238 [TBL] [Abstract][Full Text] [Related]
59. Pioglitazone ameliorates endothelial dysfunction and restores ischemia-induced angiogenesis in diabetic mice. Huang PH; Sata M; Nishimatsu H; Sumi M; Hirata Y; Nagai R Biomed Pharmacother; 2008 Jan; 62(1):46-52. PubMed ID: 17692499 [TBL] [Abstract][Full Text] [Related]
60. Effects of selective and non-selective cyclo-oxygenase inhibition on endothelial function in patients with rheumatoid arthritis. Wong M; Jiang BY; McNeill K; Farish S; Kirkham B; Chowienczyk P Scand J Rheumatol; 2007; 36(4):265-9. PubMed ID: 17763203 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]